Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.69 |
| ▸ | FLT1 | P17948 | 3/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 5/20 | 0.61 |
| ▸ | CDK4 | P11802 | 4/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.61 |
| ▸ | CCND1 | P24385 | 4/20 | 0.61 |
| ▸ | CCND3 | P30281 | 4/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | TYK2 | P29597 | 2/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.61 |
| ▸ | ITK | Q08881 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952586 | 0.91 | ITK (0.69) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5951323 | 0.91 | FGFR1 (0.64) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5952244 | 0.91 | FGFR1 (0.64) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5508118 | 0.89 | PDPK1 (0.74) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5951869 | 0.88 | FGFR1 (0.60) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5951976 | 0.88 | WNT1 (0.69) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL3521153 | 0.86 | CHEK1 (0.83) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5952338 | 0.86 | PDPK1 (0.59) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5952893 | 0.86 | FGFR1 (0.57) | FGFR1FLT1CHEK1CDK2CDK4 | |
| SCHEMBL5952183 | 0.84 | FGFR1 (0.61) | FGFR1FLT1CHEK1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | FGFR1 583/4885FLT1 2074/4885CHEK1 286/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | FGFR1 254/4885FLT1 1117/4885CHEK1 321/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | FGFR1 48/4885FLT1 4/4885CHEK1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.